HC Wainwright Reaffirms Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX)

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright's price objective would suggest a potential upside of 210.08% from the company's current price. HC Wainwright also issued estimates for Amylyx Pharmaceuticals' Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.43) EPS and FY2029 earnings at $0.07 EPS.

A number of other analysts also recently commented on AMLX. Baird R W upgraded Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. Robert W. Baird upgraded Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $3.00 to $11.00 in a research report on Monday, November 18th. Four analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Amylyx Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $7.33.

Amylyx Pharmaceuticals Trading Up 7.2 %

AMLX traded up $0.26 during midday trading on Wednesday, reaching $3.87. The company's stock had a trading volume of 1,926,461 shares, compared to its average volume of 1,574,089. The stock has a market cap of $265.28 million, a P/E ratio of -1.01 and a beta of -0.51. The company has a fifty day simple moving average of $3.53 and a 200 day simple moving average of $3.88. Amylyx Pharmaceuticals has a twelve month low of $1.58 and a twelve month high of $7.27.

Remove Ads

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The business had revenue of ($0.67) million during the quarter. Sell-side analysts expect that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Justin B. Klee sold 7,471 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $4.04, for a total transaction of $30,182.84. Following the completion of the transaction, the chief executive officer now owns 3,176,788 shares in the company, valued at $12,834,223.52. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joshua B. Cohen sold 11,851 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $3.47, for a total value of $41,122.97. Following the sale, the chief executive officer now directly owns 3,201,247 shares of the company's stock, valued at $11,108,327.09. This represents a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,169 shares of company stock worth $97,274 in the last 90 days. 11.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of AMLX. Blue Trust Inc. increased its holdings in Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock valued at $26,000 after purchasing an additional 4,883 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at $45,000. Alpine Global Management LLC acquired a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at $45,000. RPO LLC acquired a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at $46,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at $53,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.